Phaseline

Targets › GRN

GRN (Progranulin): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 4 Phase 1; Neurology; next expected readout Apr 2027.

Secreted protein that acts as a key regulator of lysosomal function and as a growth factor involved in inflammation, wound healing and cell proliferation. Regulates protein trafficking to lysosomes, and also the activity of lysosomal enzymes. (UniProt, P28799)

Open in Phaseline: the race on GRN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AviadoBioAVB-101
AAV9-delivered GRN gene therapy
GRNPhase 1Frontotemporal DementiaApr 2027
Voyager TherapeuticsVY1706
AAV9-delivered progranulin (GRN) gene therapy
GRNPhase 1Alzheimer s DiseaseApr 2029
Prevail TherapeuticsLY3884963
Gene therapy delivering PGRN (progranulin) to increase progranulin protein levels
GRNPhase 1Frontotemporal DementiaNov 2029
Passage BioPBFT02
Gene therapy delivering functional GRN gene to the brain
GRNPhase 1Frontotemporal Dementia–

Conditions

Frontotemporal Dementia (3) Alzheimer s Disease (1)

Modalities

small molecule (2), mixed (1), other (1)

Companies

Prevail Therapeutics (1) AviadoBio (1) Voyager Therapeutics (1) Passage Bio (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.